An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

Prophylactic vaccines for SARS-CoV-2 have lowered the incidence of severe COVID-19, but emergence of viral variants that are antigenically distinct from the vaccine strains are of concern and additional, broadly acting preventive approaches are desirable. Here, we report on a glycolipid termed 7DW8-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Moriya, Nair, Manoj S., Masuda, Kazuya, Castagna, Candace, Chong, Zhenlu, Darling, Tamarand L., Seehra, Kuljeet, Hwang, Youngmin, Ribeiro, Ágata Lopes, Ferreira, Geovane Marques, Corredor, Laura, Coelho-dos-Reis, Jordana Grazziela Alves, Tsuji, Yukiko, Mori, Munemasa, Boon, Adrianus C. M., Diamond, Michael S., Huang, Yaoxing, Ho, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319732/
https://www.ncbi.nlm.nih.gov/pubmed/37402814
http://dx.doi.org/10.1038/s41467-023-39738-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319732/
https://www.ncbi.nlm.nih.gov/pubmed/37402814
http://dx.doi.org/10.1038/s41467-023-39738-1

Ejemplares similares